Tiny polymer tubes coated with zinc may one day be able to treat stomach conditions such as ulcers by acting as "micromotors" carrying drugs to the stomach lining. Animal studies at the University of California, San Diego, demonstrated in vivo that the synthetic motors enhanced the efficiency of drug delivery to the stomach.
Cashing in on the current enthusiasm in venture circles for gene therapy upstarts, ReGenX has snagged a $30 million round that will finance a round of new hires as it sets sail for the clinic with lead programs for rare diseases of the central nervous system.
Over the past 6 months the up-and-coming Zymeworks has leveraged its expertise in bispecific antibodies into expanded development pacts with two marquee Big Pharma partners. Later today, positioning itself for what it sees as a pivotal year, the biotech plans to announce another research deal with the prolific Big Biotech Celgene, which is inking one of its classic collaborations sweetened by an upfront payment, an equity stake and up to $164 million per project for a slate of programs that represent its biggest potential payoff yet.
Johnson & Johnson has opened the doors on its Takeda-partnered biotech incubator in Israel, enrolling its first class of startups and advancing its global plan to accelerate R&D through external innovation.
Amid an industrywide re-embrace of RNA-based therapies, pioneering biotech Alnylam is plotting to raise $450 million in a public offering, keeping its eye out for pipeline-building acquisitions.
France's Carmat reached another milestone in its quest to bring its artificial heart to market, as a patient who received the device in August has recovered enough to return home.
In-transition drug developer AMRI has won a 10-year contract with the National Institutes of Health to help develop and manufacture neurological drugs.
The R&D innovators at Evotec have signed a deal to lend their drug discovery muscle to U.K. biotech C4X Discovery, hoping to develop selective drugs that can combat addiction without druggy side effects.
Catalent has signed a collaboration deal with pharma giant Sanofi, lending out its proprietary approach to crafting antibody-guided treatments.
Genomics data provider Metanome and Companion PBx, a company that's developing microbiome-based nutritional products for cats and dogs, have formed a new partnership to develop a sample collection kit and web-based survey, which will be used to build a microbiome database containing information on thousands of healthy and sick dogs.